Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2

Keyphrases

• Breast Cancer Patients 100%
• Vaccination 100%
• Dendritic Cells 100%
• Specific T Cells 100%
• Lymphocyte Subsets 100%
• Low-dose interleukin-2 100%
• P53 Peptide 100%
• Clinical Outcomes 33%
• Blood Samples 33%
• Fresh Whole Blood 33%
• Tumor 33%
• Patients Included 33%
• In Vitro Activation 33%
• Nave 33%
• Progressive Disease 33%
• Chemotherapy 33%
• Cancer Patients 33%
• Derived Peptide 33%
• T Cells 33%
• CD8+ T Cells 33%
• Metastatic Breast Cancer 33%
• Interleukin-4 (IL-4) 33%
• Granulocyte Colony-stimulating Factor (G-CSF) 33%
• Phase II Clinical Trial 33%
• Overexpression 33%
• CD28 33%
• CD4+CD25+ Regulatory T Cells 33%
• CD-8 33%
• Effector Memory T Cells 33%
• Qualitative Change 33%
• Stable Disease 33%
• Cancer Vaccine 33%
• HLA-A2 33%
• HLA-A*0201 33%
• CD27 33%
• Wild-type p53 33%
• Quantitative Change 33%
• Low-dose IL-2 33%
• T Cell Subpopulations 33%
• Vaccine Trial 33%
• Dextramers 33%
• Multicolor 33%

Immunology and Microbiology

• T Cell 100%
• Vaccination Policy 100%
• Dendritic Cell 100%
• Low Drug Dose 100%
• Interleukin 2 100%
• P53 100%
• Lymphocyte Subpopulation 100%
• CD4 33%
• Vaccine Efficacy 16%
• Wild Type 16%
• Cytotoxic T-Cell 16%
• CD8 16%
• Immunotherapy 16%
• Granulocyte Macrophage Colony-Stimulating Factor 16%
• CD28 16%
• Regulatory T Cell 16%
• Memory T Cell 16%
• Cancer Vaccine 16%
• Fluorescence Activated Cell Sorting 16%
• T Lymphocyte Subpopulation 16%